What is blastic plasmacytoid dendritic cell neoplasm?
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive blood cancer. It develops from the early forms of plasmacytoid dendritic cells, immune cells that normally help the body fight viruses by releasing interferon.
BPDCN usually starts in the skin. Most people first notice bruise-like purple patches or lumps. The disease often also involves the bone marrow, blood, lymph nodes and spleen, and it can reach the brain and spinal fluid.
Because it can look like a skin lymphoma or a leukaemia, BPDCN was known by several names in the past, including “blastic NK-cell lymphoma”. It is now classed among the myeloid cancers, close to acute myeloid leukaemia (AML).
BPDCN grows quickly and needs prompt treatment. Since 2018, a targeted drug called tagraxofusp, which attacks the CD123 protein on BPDCN cells, has been available. For fit patients, a donor stem cell transplant in first remission offers the best chance of long-term control.
1. Key facts at a glance
| Feature | Details |
|---|---|
| How common | Very rare; under 1% of acute leukaemias |
| Typical age | Mostly over 60; median age about 65-70. A smaller group of cases occurs in children and young adults |
| Sex | About 3 times more common in men |
| First sign | Skin lesions in about 80-90% |
| Other sites | Bone marrow, blood, lymph nodes, spleen, brain and spinal fluid |
| Key marker | CD123 with CD4, CD56, TCL1 and TCF4 |
| Main treatments | Tagraxofusp, intensive leukaemia-type chemotherapy, venetoclax combinations, donor stem cell transplant |
| Outlook | Historically poor (median survival about 1-1.5 years); better after transplant in first remission |
2. Causes and risk factors
The cause is not known. BPDCN is not inherited and not contagious.
| Factor | Notes |
|---|---|
| Age | Mainly affects older adults |
| Male sex | Much more common in men; genes on the X chromosome, such as ZRSR2, may play a role |
| Acquired gene changes | Mutations in genes such as TET2, ASXL1, ZRSR2, NRAS and IKZF1, similar to those seen in other myeloid blood cancers |
| Other blood disorders | Some people have, or later develop, myelodysplastic syndrome, chronic myelomonocytic leukaemia or AML |
2.1 What plasmacytoid dendritic cells normally do
Plasmacytoid dendritic cells are a small group of immune cells that circulate in the blood and settle in lymph nodes and other tissues. When they detect a virus, they release large amounts of type I interferon, a chemical signal that switches on the body’s antiviral defences.
In BPDCN, immature forms of these cells grow out of control. They seem to be strongly attracted to the skin, which explains why skin lesions are so common. They carry high levels of the CD123 receptor for interleukin-3, which is why drugs targeting CD123 can work.
3. How does it look?
3.1 On the skin
| Type of lesion | What it looks like |
|---|---|
| Nodules | Firm, painless, purple, plum-coloured or bruise-like lumps, often on the face, scalp, trunk or limbs |
| Bruise-like patches | Flat, dusky purple or brown areas that look like bruises but do not fade |
| Plaques | Raised, thickened areas of skin |
| Widespread disease | Many lesions over the body |
| Ulcers | Uncommon |
The skin lesions are usually not itchy or painful, which can delay medical review.
3.2 Elsewhere in the body
| Site | What may be found |
|---|---|
| Lymph nodes | Painless swollen glands in the neck, armpit or groin |
| Spleen and liver | Enlargement |
| Mouth | Occasionally, lesions in the gums or mucous membranes |
| Brain and spinal fluid | Often without symptoms at first, but found on spinal fluid testing |
3.3 Under the microscope
| Feature | Description |
|---|---|
| Cells | Medium-sized, immature (blast-like) cells with fine chromatin and scanty cytoplasm |
| Skin pattern | The cells fill the dermis and fat below it, usually sparing the top layer of skin (epidermis) |
| Markers | Positive for CD123, CD4, CD56, TCL1, TCF4 and CD303; negative for myeloperoxidase and for T- and B-cell lineage markers |
| Bone marrow | Often involved, sometimes with signs of myelodysplasia |
4. Symptoms
| Symptom | Details |
|---|---|
| Skin lumps or bruise-like patches | The most common first sign; they may grow over weeks to months |
| Swollen glands | In about half of people |
| Tiredness and breathlessness | From anaemia when the bone marrow is involved |
| Infections | From low white cell counts |
| Bleeding or easy bruising | From low platelets |
| Fullness or discomfort in the left upper abdomen | From an enlarged spleen |
| Headache, confusion or nerve problems | Rare, with brain or spinal fluid involvement |
| Fever, sweats, weight loss | Less common |
See a doctor for any purple or bruise-like skin lump that does not fade within a few weeks, particularly if you are over 60 or feel unwell.
5. Diagnosis
| Test | Purpose |
|---|---|
| Skin biopsy | The usual first step; diagnosis needs special stains |
| Immunohistochemistry and flow cytometry | Confirms the BPDCN markers (CD123, CD4, CD56, TCL1, TCF4) |
| Blood count and blood film | Looks for abnormal cells and low counts |
| Bone marrow biopsy | Checks for marrow involvement |
| Lumbar puncture | Checks the spinal fluid; also used to give preventive treatment |
| PET-CT or CT scan | Looks for lymph node, spleen and other organ involvement |
| Genetic tests | Mutations and chromosome changes that help separate BPDCN from AML with similar features |
| Albumin, liver and kidney tests | Needed before tagraxofusp |
BPDCN can be confused with skin lymphomas, myeloid sarcoma (leukaemia in the skin) and AML, so review by an experienced haematopathologist is important.
5.1 Conditions that can look similar
| Condition | How it differs from BPDCN |
|---|---|
| Bruising | Ordinary bruises change colour and fade within 2-3 weeks; BPDCN lesions persist or grow |
| Cutaneous T-cell or B-cell lymphoma | Lymphoma cells carry T- or B-cell markers, which BPDCN cells lack |
| Myeloid sarcoma or AML in the skin | Usually positive for myeloperoxidase or monocytic markers; may also express CD123, so a full panel of stains is needed |
| Mature plasmacytoid dendritic cell proliferation | A clump of mature dendritic cells linked to some myeloid neoplasms, often chronic myelomonocytic leukaemia; it behaves differently |
| Merkel cell carcinoma | A skin cancer of older adults that can also form purple-red nodules, but has neuroendocrine markers |
6. Treatment
Treatment should be given at a specialist haematology centre. Choice depends on fitness, age and whether a transplant is possible.
6.1 First treatment
| Treatment | Key points |
|---|---|
| Tagraxofusp | A protein drug made from interleukin-3 joined to a toxin. It targets CD123. In the main trial, about 57% of previously untreated patients achieved a complete response. Approved in the United States since 2018 and in Europe since 2021 |
| Intensive chemotherapy | Regimens used for acute lymphoblastic leukaemia (such as hyper-CVAD) or for AML; high response rates in fit patients |
| Venetoclax combinations | Venetoclax with azacitidine or chemotherapy is being studied and used in some centres |
| Treatment of the brain and spinal fluid | Chemotherapy injected into the spinal fluid to treat or prevent central nervous system disease |
| Radiotherapy | For a single skin lesion or to relieve symptoms |
6.2 Stem cell transplant
| Type | Role |
|---|---|
| Allogeneic (donor) transplant | Offers the best chance of long-term remission when performed in first complete remission in fit patients. Reduced-intensity conditioning allows some older adults to have it |
| Autologous transplant | Sometimes used for patients without a donor, though the evidence is more limited |
6.3 Relapsed disease
Relapse is common. Options include tagraxofusp if not used before, venetoclax-based treatment, other chemotherapy, a donor transplant if not done before, and clinical trials of new CD123-targeted drugs.
6.4 Side effects of treatment
| Treatment | Main side effects |
|---|---|
| Tagraxofusp | Capillary leak syndrome: fluid leaks from blood vessels, causing swelling, weight gain, low albumin and low blood pressure. Treatment is given in hospital for at least the first cycle with daily weight and albumin checks. Also liver enzyme rises, low platelets and tiredness |
| Intensive chemotherapy | Low blood counts, infections, mouth sores, hair loss, nausea |
| Stem cell transplant | Serious infections, graft-versus-host disease |
6.5 How treatment is chosen
| Patient situation | Typical approach |
|---|---|
| Fit, transplant possible | Tagraxofusp or intensive chemotherapy to reach remission, spinal fluid treatment, then a donor stem cell transplant in first remission |
| Fit, no donor available | Remission treatment followed by continued therapy or, in some cases, an autologous transplant |
| Older or less fit | Tagraxofusp alone, or lower-intensity treatment such as azacitidine with venetoclax; the focus is on disease control and quality of life |
| Very frail or with other serious illness | Gentle treatment and supportive care, sometimes radiotherapy to troublesome skin lesions |
| Children and young adults | Often treated with acute lymphoblastic leukaemia-type protocols, which have given good results in this group |
Because BPDCN is so rare, joining a clinical trial is encouraged whenever one is available. Trials are testing new CD123-targeted antibody-drug conjugates, combination treatments and maintenance after transplant.
7. Outlook (prognosis)
| Situation | Approximate outlook |
|---|---|
| Overall, historical data | Median survival about 12-18 months |
| Complete remission followed by donor transplant | Long-term survival in a substantial proportion; about half in some series |
| Older or less fit patients not able to have intensive treatment | Remissions often shorter |
| Children | Often respond better to treatment than adults |
| Skin-only disease | May do better than disease that already involves the marrow, but still needs systemic treatment |
8. Follow-up
| What | How often |
|---|---|
| Clinic visit and skin examination | Every 1-3 months in the first years |
| Blood tests | At each visit |
| Bone marrow test | To confirm remission and if counts change |
| Spinal fluid tests | During treatment as planned |
| After transplant | Close follow-up by the transplant team |
9. Living with BPDCN
| Topic | Practical advice |
|---|---|
| Skin lesions | They usually shrink quickly with treatment; report any new ones promptly as they may be a sign of relapse |
| Infection precautions | Report a temperature of 38 C or more straight away |
| Fluid and weight checks | During tagraxofusp, tell your team about swelling, rapid weight gain or breathlessness |
| Emotional support | A rare, fast-moving cancer can be overwhelming; specialist nurses and patient groups can help |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is BPDCN a skin cancer? | No. It is a blood cancer that often shows itself first in the skin |
| Is it a lymphoma or a leukaemia? | It is now classed with myeloid neoplasms, close to acute myeloid leukaemia, although older texts called it a lymphoma |
| Can it be cured? | Some people achieve long-term remission, especially after a donor stem cell transplant in first remission |
| Why is CD123 important? | Nearly all BPDCN cells carry CD123, so it is used for diagnosis and as the target of tagraxofusp |
| Is it inherited? | No |
| Will the skin lesions leave scars? | They usually fade completely with treatment, sometimes leaving slight discolouration |
| Do I need to stay in hospital? | The first cycle of tagraxofusp and most intensive chemotherapy are given in hospital. Later cycles may be given as an outpatient in some centres |
Resources
- Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms’, Leukemia, 36(7), pp. 1703-1719.
- Arber, D.A. et al. (2022) ‘International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data’, Blood, 140(11), pp. 1200-1228.
- Pagano, L. et al. (2016) ‘Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches’, British Journal of Haematology, 174(2), pp. 188-202.
- Garnache-Ottou, F. et al. (2019) ‘How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?’, Blood Advances, 3(24), pp. 4238-4251.
- Julia, F. et al. (2013) ‘Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients’, British Journal of Dermatology, 169(3), pp. 579-586.
- Taylor, J. et al. (2019) ‘Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark’, Blood, 134(8), pp. 678-687.
- Pemmaraju, N. et al. (2019) ‘Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm’, New England Journal of Medicine, 380(17), pp. 1628-1637.
- Pemmaraju, N. et al. (2022) ‘Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm’, Journal of Clinical Oncology, 40(26), pp. 3032-3036.
- Roos-Weil, D. et al. (2013) ‘Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation’, Blood, 121(3), pp. 440-446.
- Sapienza, M.R. et al. (2020) ‘Molecular features of blastic plasmacytoid dendritic cell neoplasm: DNA mutations and epigenetics’, Hematology/Oncology Clinics of North America, 34(3), pp. 511-521.
- National Cancer Institute (2026) NCI Dictionary of Cancer Terms: blastic plasmacytoid dendritic cell neoplasm. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/blastic-plasmacytoid-dendritic-cell-neoplasm (Accessed: October 2026).
Prepared by the editorial team, October 2026.